ADPKD Connective Tissue Disorder Link

ADPKD 结缔组织疾病链接

基本信息

项目摘要

DESCRIPTION (provided by applicant): We have discovered a novel microfibril protein, named vascular matrix protein (VMP) which is extensively expressed in the media of large to medium sized blood vessels. Our evidence indicates that this protein is an alternative transcript arising from the PKD1 locus, the gene that codes for. Several lines of evidence support the conclusion that VMP is a component of matrix microfibrils. Extraction of VMP from tissue requires conditions similar to that described for other microfibril components such as fibrillin 1, 2, microfibril associated glycoprotein and elastin. VMP co-localized with fibrillin-1, fibrillin-2, elastin and microfibril associated glycoprotein (MAGP-1) as determined by immunohistochemistry and electron microscopy. Tissue etching with 6 M guanidinium chloride optimizes immunofluorescence labeling of tissue with anti-VMP. Discovery of VMP may account for the extra-renal manifestations of ADPKD which bears similarities to connective tissue disorders. Mutations in VMP may also account for the description of 2 families with ADPKD and connective tissue disorders. Strikingly these families phenotypically resemble a Marfan phenotype, yet their overlap connective tissue disorder linked to the PKD1 locus on chromosome 16 (Somlo et al., JASN, vol 4, 1371-8, 1993). Identification of another transcript encoded which codes for an extracellular matrix microfibril may also explain the finding that PKD1 knockout mice, generated by deletions from the 3' end of PKD1, have a fetal lethal phenotype due to increased vascular permeability, cardiac defects and subcutaneous hemorhages (Kim et al., PNAS, vol 97, 1731-35, 2000). VMP is ectopically expressed in the renal interstitium only in the setting of kidney cyst formation. This suggests that VMP expression is linked to epithelial growth abnormalities that lead to cyst formation. The goals of this proposal are to unambiguously identify the gene that codes for VMP, determine the biogenesis of VMP and examine its potential role in cystogenesis or nephrogenesis. RELEVANCE TO PUBLIC HEALTH-Polycystic kidney disease is the most common genetic cause of renal failure in the United States. Better understanding of the disease process will lead to therapies that halt progression of renal failure thereby decreasing the number of patients on dialysis.
描述(由申请人提供):我们发现了一种新型微纤维蛋白,称为血管基质蛋白(VMP),它在大中型血管的培养基中广泛表达。我们的证据表明,这种蛋白质是一种替代转录产生的PKD 1基因座,基因的代码。有几条证据支持VMP是基质微纤维组分的结论。从组织中提取VMP需要类似于对其他微纤维组分如明胶1、2、微纤维相关糖蛋白和弹性蛋白所述的条件。免疫组化和电子显微镜观察显示VMP与VMP-1、VMP-2、弹性蛋白和微纤维相关糖蛋白(MAGP-1)共定位。用6 M氯化胍进行组织蚀刻可优化抗VMP组织的免疫荧光标记。VMP的发现可以解释ADPKD的肾外表现,其与结缔组织疾病相似。VMP突变也可能解释了2个ADPKD和结缔组织疾病家族的描述。引人注目的是,这些家族在表型上类似于马凡氏表型,但它们与染色体16上的PKD 1基因座相关的重叠结缔组织疾病(Somlo et al.,J. J.,第4卷,1371-8,1993)。编码细胞外基质微纤维的另一种转录物的鉴定也可以解释这样的发现,即通过从PKD 1的3'端缺失产生的PKD 1敲除小鼠由于增加的血管通透性、心脏缺陷和皮下出血而具有胎儿致死表型(Kim等人,PNAS,第97卷,1731-35,2000)。VMP仅在肾囊肿形成时异位表达于肾间质。这表明VMP表达与导致囊肿形成的上皮生长异常有关。该提案的目标是明确识别编码VMP的基因,确定VMP的生物发生并检查其在膀胱发生或肾发生中的潜在作用。与公共卫生的相关性-多囊肾病是美国最常见的肾衰竭遗传原因。更好地了解疾病过程将导致停止肾衰竭进展的治疗,从而减少透析患者的数量。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT L BACALLAO其他文献

ROBERT L BACALLAO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT L BACALLAO', 18)}}的其他基金

Mitochondria Functions Modified by Sulfotransferase 1C2
磺基转移酶 1C2 修饰的线粒体功能
  • 批准号:
    10230976
  • 财政年份:
    2020
  • 资助金额:
    $ 15.15万
  • 项目类别:
Mitochondria Functions Modified by Sulfotransferase 1C2
磺基转移酶 1C2 修饰的线粒体功能
  • 批准号:
    10664935
  • 财政年份:
    2020
  • 资助金额:
    $ 15.15万
  • 项目类别:
Mitochondria Functions Modified by Sulfotransferase 1C2
磺基转移酶 1C2 修饰的线粒体功能
  • 批准号:
    10016916
  • 财政年份:
    2020
  • 资助金额:
    $ 15.15万
  • 项目类别:
Endogenous Mitochondria Resistance to Acute Kidney Injury
内源性线粒体对急性肾损伤的抵抗力
  • 批准号:
    8971622
  • 财政年份:
    2014
  • 资助金额:
    $ 15.15万
  • 项目类别:
Reducing Nephrotoxicity while enabling read through of missense stop codons by Gentamicin congeners
降低肾毒性,同时能够通过庆大霉素同系物读取错义终止密码子
  • 批准号:
    9898260
  • 财政年份:
    2011
  • 资助金额:
    $ 15.15万
  • 项目类别:
Polycystic Kidney Disease: Basic, Translational, and Clinical Science
多囊肾病:基础科学、转化科学和临床科学
  • 批准号:
    7541112
  • 财政年份:
    2008
  • 资助金额:
    $ 15.15万
  • 项目类别:
ADPKD Connective Tissue Disorder Link
ADPKD 结缔组织疾病链接
  • 批准号:
    7230235
  • 财政年份:
    2006
  • 资助金额:
    $ 15.15万
  • 项目类别:
Renal Molecular Cell Biology Training Program
肾分子细胞生物学培训项目
  • 批准号:
    6735608
  • 财政年份:
    2003
  • 资助金额:
    $ 15.15万
  • 项目类别:
Renal Molecular Cell Biology Training Program
肾分子细胞生物学培训项目
  • 批准号:
    6896524
  • 财政年份:
    2003
  • 资助金额:
    $ 15.15万
  • 项目类别:
Renal Molecular Cell Biology Training Program
肾分子细胞生物学培训项目
  • 批准号:
    7256876
  • 财政年份:
    2003
  • 资助金额:
    $ 15.15万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.15万
  • 项目类别:
    Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
  • 批准号:
    10828252
  • 财政年份:
    2023
  • 资助金额:
    $ 15.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了